GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — were originally intended to treat type 2 diabetes and obesity. But in recent months, studies have shown that these popular medications can have numerous other health benefits. Some have even claimed that GLP-1s could eventually become the new “everything […]
Wednesday, October 07, 2026